Member Info for Brand

CONCLUSION

A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men. In these patients, adaptive autoimmunity impairs innate and intrinsic antiviral immunity. These findings provide a first explanation for the excess of men among patients with life-threatening COVID-19 and the increase in risk with age. They also provide a means of identifying individuals at risk of developing life-threatening COVID-19 and ensuring their enrolment in vaccine trials. Finally, they pave the way for prevention and treatment, including plasmapheresis, plasmablast depletion, and recombinant type I IFNs not targeted by the auto-Abs (e.g., IFN-ß).

There's more :)

https://www.science.org/doi/10.1126/sciimmunol.abl4340?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

TLDR - it's good :)
https://www.science.org/doi/10.1126/science.abd4585?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Full details of the FDA meeting here

https://www.fda.gov/advisory-committees/advisory-committee-calendar/november-30-2021-antimicrobial-drugs-advisory-committee-meeting-announcement-11302021-11302021

Cant even begin to imagine what the SP would do if SNG were in an all day live broadcast meeting for EUA.

It's a breakdown of just about everything, so too long to post outright, but here's our bit

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANS

Interferons
Interferons are molecules our cells naturally produce in response to viruses. They have profound effects on the immune system, rousing it to attack the invaders, while also reining it in to avoid damaging the body’s own tissues. Injecting synthetic interferons is now a standard treatment for a number of immune disorders. Rebif, for example, is prescribed for multiple sclerosis.

As part of its strategy to attack our bodies, the coronavirus appears to tamp down interferon. That finding has encouraged researchers to see whether a boost of interferon might help people weather Covid-19, particularly early in infection. Early studies, including experiments in cells and mice, have yielded encouraging results that have led to clinical trials.

On July 20, the British pharmaceutical company Synairgen announced that an inhaled form of interferon called SNG001 lowered the risk of severe Covid-19 in infected patients in a small clinical trial. They later published the details of the study in a medical journal, and in February SNG001 was given to participants in a large, ongoing clinical trial run by the National Institute of Health. On Oct. 20, Synairgen announced that the drug was advancing into a Phase 3 trial in mild to moderate COVID-19 patients.

Last August, the National Institute of Allergy and Infectious Diseases launched a Phase III trial on Rebif — the drug used for multiple sclerosis — combined with the antiviral remdesivir. The trial is completed, but the results have yet to be made public.
Updated Oct. 26
Antivirals

This is pure speculation on my behalf, but considering Dr Castros first remark about sng moving forward was in the summer, RNS about phase 3 was months go now, do we really think Activ phase 3 hasn't started dosing yet?

Disclaimer - I don't know the specifics of what synairgen is required to inform the market of if it's not their trial.

Also worth keeping in mind that Activ phase 3 isn't vs placebo, it's Vs other drug.

From my best understanding of ACTIV, just about anything is possible. At the end of the day, it's a govt testing drugs not a pharma trying to prove something works, So they get to choose when a threshold has been reached.

Yknow when the usual suspects show up I know something good is about to go down :)

Lol

Fruits, that was a great post thank you :)

I found myself slap bang in the middle of the seafaring industry through this pandemic and I must say everything you've said fits exceptionally well with what I have seen. I've been invested for coming up on a year in SNG and I must say that RM and the team at SNG have given me great confidence they will bring this ship home safe and sound.

Not long to go now

I've been trying to put myself in RMs/BODs shoes with a view to the next few weeks...

With P3 sprinter now completed, there is no doubt the big pharma hawks are now circling, certainly aware of the much higher costs of running sng the company (all that top end talent ain't cheap) and the cash that will be required to produce sng001 at any scale.

So as we approach D day in late Dec/Jan, would sng want to have a sp under £2? This would surely make the company more vulnerable to hostile take overs, ii games and general market shenanigans no?

So on that basis, I am expecting some sort of news before the news, whether its efficacy data from Activ, pre-orders from govts, delta data or otherwise - probably followed up with a PR campaign targeting mass media with interviews and the like.

Just my humble opinion but it would seem like the prudent move to make. Holding tight here. GLA

https://ir.sabbiotherapeutics.com/news-releases/news-release-details/sab-biotherapeutics-reports-third-quarter-2021-financial-results

This seems pretty good

'Lee and Nayak, in collaboration with researchers in the laboratory of immunologist Peter Jackson, PhD, to found that laboratory-grown human nasal tissues that were exposed to cigarette smoke were more susceptible to infection by the SARS-CoV-2 virus than those that were not exposed to smoke. And adding extra interferon beta to the dish before exposing the cells to the smoke prevented infection with the virus.

"These findings highlight the central role of interferon beta in mediating susceptibility to SARS-CoV-2 in smokers," Lee said.'

Thank you Matterhorn - brilliant explanation, much appreciated.

Ive had a look at CFDs over the weekend.

Is what's essentially happened here is Poly had 'shared ownership' of 5mil odd shares (2.5%t) hrough some sort of hedged arrangement with JPM, Jefferies etc and now they have taken 'full ownership' of those shares?

Very well stated Axe

Would add that if this:

'You have a horse running that has an even chance of winning, but is priced at 5/1. Do you remortgage your house and stick it all on?'

:Is how you are currently looking at this opportunity - you clearly don't have a clue what you are doing and should stick to the ponies, let the grown ups do their thing yeah.

Even in the incredibly unlikely event sprinter doesn't meet its endpoints (have a read of the huge volume of data re INFb and covid) There is still Activ2 and COPD plays. (COPD estimated at 8b by RM himself in 2018)

So while yes, there is a slim chance this trial doesn't succeed, it would by no means be the end for SNG

I don't seem to be able to raise the article, but maybe it's just a preview, not published yet?

Anyway, this bit from the abstract got my attention:

'Also combined regimens with antivirals or with compounds which are able to enhance the endogenous production of interferon might be of promise.'

This is the thing w the Merck/PF/AZ etc pills. With SNG, We have something that could potentially accelerate so many other treatments, for Covid and beyond.

A potential genuine scientific breakthrough :)

It's the cure for the common cold. We've been at it for a fair bit longer than 20 years.